There is ample evidence that the compensatory secretion of adrenal steroids occurs after estrogen administration and castration as the treatment for prostatic carcinoma. Thus, the adrenal androgens dehydroepiandrosterone (RHEA), dehydroepiandrosterone sulfate (DHEAS) and 4-androstenedione have been postulated to facilitate the growth of prostatic carcinoma, despite the loss of testicular function by estrogen therapy.
Based on this, pituitary ablation, corticosteroid therapy and adrenalectomy have been established as therapeutic programs for relapsing prostatic carcinoma. However, it is still controversial whether the synthesis of adrenal androgens is stimulated concomitantly with hypersecretion of corticosteroid resulted from hyperplasia of the adrenal cortex following estrogen therapy and castration. Furthermore, it is also unknown whether the adrenal androgens trigger the reactivation of prostatic carcinoma.
For the purpose to elucidate the problems mentioned above the evaluation of the basic androgen milieu in patients with prostatic carcinoma treated with estrogen and gestagen, and the determination of 4-androstenedione concentrations in peripheral plasma by a specific radioimmunoassay in several clinical conditions of prostatic carcinoma were employed as the experimental design for the studies.
The results in the present paper were summarized as follows:
1) Plasma 4-androstenedione levels in normal men, normal women and normal aged men were 81±38 (M1±SD, n=10), 105±22 (M±SD, n=10) and 73±28 (MSD, n=9), respectively. Similarly, the androgen levels in benign prostatic hypertrophy and prostatic carcinoma were 74±22 (M±SD, n=21) and 52±25 (M±SD, n=9), respectively. In the plasma 4-androstenedione level, there is no statistically significant discrepancy between benign prostatic hypertrophy and prostatic carcinoma in the comparison with normal aged men. Furthermore the concentration of 4-androstenedione in the morning was 20 per cent higher than that in the afternoon.
2) The testosterone levels in 15 patients treated with 30mg daily of hexestrol for 1 to 8 years were 34.5±19.7 (M±SD). The low level of plasma testosterone was maintained with estrogen treatment at least up to 8 years.
3) The formation of testosterone from progesterone
3H- in the testicular tissue in vitro was definitely inhibited by oral administration with more than 30mg daily of hexestrol, 3mg daily of diethylstilbestrol or more than 200mg daily of diethylstilbestrol diphosphate.
4) The plasma 4-androstenedione in the patients treated with 30mg daily of hexestrol for 1 to 9 years was 52.9±20.0 (M±SD, n=29). No patients who have the plasma 4-androstenedione over the normal level were recognized during the estrogen therapy, while plasma cortisol level following estrogen therapy was three times higher than the normal level. It is also observed that the plasma androgen in the patients treated with 100 mg daily of chlormadinone acetate for 6 years remained within normal level.
5) The plasma 4-androstenedione concentrations in 8 relapsing prostatic carcinoma were within the range of normal aged men.
It is reasonably concluded that there is no tendency to stimulate the synthesis of adrenal androgen in the long term treatment with estrogen or chlormadione acetate, and that the adrenal androgens particularly 4-androstenedione can not become a trigger for reactivation of prostatic carcinoma.
View full abstract